CTIS change paradigm for image interpretation and management

The goal of MEDIAN CTIS is to dramatically improve the image interpretation and management process in oncology clinical trials through the deployment of our web based solutions at all sites participating in a trial including Independent Review sites if required.

All clinical trials phases have different concerns, from early to post approval. MEDIAN CTIS is designed to address these specific requirements.

MEDIAN CTIS provide :

Enhanced Clinical Trials diagnostic tools based on the MEDIAN LMS platform, to standardize the production of a given criteria such as RECIST directly at investigator sites in an automated process thereby reducing the inter reader variability.
Fully Normalized and Automated image workflow among all stakeholders (sites, independent reviewers, sponsors)
All sites to be automatically linked to a common central database in the cloud and to feed the database with images linked to quantitative lesion data, allowing

sponsors in a phase II to have a real time dashboard of the ongoing trial for go/nogo decisions or for real time feedback in the case of adaptive design trials,
sponsors to correlate imaging data with other markers such as genomic or genetic markers,
retrospective studies to analyze subset of patient for profiling of responders

Advanced imaging biomarkers, such as volume, evolution of necrotic tissue and more.

Fleche As of today, imaging represents 10-15% of oncology clinical trial budgets.

Through the convergence of advanced Imaging Technologies and its cloud computing platform, CTIS generates better quality data.

In combining improved quality of data and streamlined workflow, MEDIAN CTIS allows better study management, time reduction and ultimately fewer patients to recruit.

We are also entering into new paradigm whereby our cloud computing solutions can empower investigator sites to perform state of the art image interpretation.

Costly Central Independent Review will not be the gold standard of the future.